Complement-mediated killing of microtumors in vitro

American Journal of Pathology

Volumn 153, Issue 3, 1998, Pages 845-855

  Hakulinen, Juha ^a   Meri, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD59 ANTIGEN; COMPLEMENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TERATOCARCINOMA; TUMOR VOLUME;

EID: 0031655801     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65626-X     Document Type: Article

References (37)

1. Hertler AA, Frankel AE: Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 1989, 7:1932-1942
2. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 1994, 180:1-4
3. Vijayasaradhi S, Bouchard B, Houghton AN: The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990, 171:1375-1380
4. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982, 129:184-189
5. Seya T, Turner JR, Atkinson JP: Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986, 163:837-855
6. Sugita Y, Nakano Y, Tomita M: Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem (Tokyo) 1988, 104:633-637
7. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H: CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989, 170:637-654
8. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ: Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990, 71:1-9
9. Rollins SA, Zhao J, Ninomiya H, Sims PJ: Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991, 146:2345-2351
10. Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991, 65:532-537
11. Kuraya M, Yefenol E, Klein G, Klein E: Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur J Immunol 1992, 22:1871-1876
12. Kumar S, Vinci JM, Pytel BA, Baglioni C: Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993, 53:348-353
13. Hakulinen J, Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994, 71:820-827
14. Junnikkala S, Hakulinen J, Meri S: Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 1994, 24:611-615
15. Bjørge L, Vedeler CA, Ulvestad E, Matre R: Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 1994, 24:1597-1603
16. Bjørge L, Hakulinen J, Wahlström T, Matre R, Meri S: Complement regulatory proteins in ovarian malignancies. Int J Cancer 1997, 70: 14-25
17. Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S: Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996, 148:1139-1151
18. Carlsson J, Yuhas JM: Liquid-overlay culture of cellular spheroids. Recent Results in Cancer Research Edited by H Acker, J Carlson, R Durand, RM Sutherland. Berlin, Springer-Verlag, 1984, pp 1-23
19. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184
20. Chen F-M, Hansen EB, Taylor CR, Epstein AL: Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J Natl Cancer Inst 1991, 83:200-204
21. Sutherland RM, Buchegger F, Schreyer M, Vacca A, Mach J-P: Penetration and binding of radiolabeled anti-carcinoembryogenic antigen monoclonal antibodies and their antigen-binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987, 47: 1627-1633
22. Kwok CS, Cole SE, Liao SK: Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids. Cancer Res 1988, 48:1856-1863
23. Epstein AL, Chen FM, Taylor CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988, 48:5842-5848
24. Jääskeläinen J, Kalliomäki P, Paetau A, Timonen T: Effect of LAK cells against three-dimensional tumor tissue. J Immunol 1989, 142:1036-1045
25. Bjørge L, Junnikkala S, Kristofferson EK, Hakulinen J, Matre R, Meri S: Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis. Br J Cancer 1997, 75:1247-1255
26. Jokiranta TS, Meri S: Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement. J Immunol 1993, 151:2124-2131
27. Sher E, Eisman JA, Moselay JM, Martin TJ: Whole cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47D) in culture. Biochem J 1981, 200:315-320
28. Zeuthen J, Norgaard JOR, Avner P, Fellous M, Wartiovaara J, Vaheri A, Rosen A, Giovanella BC: Characterization of human ovarian teratocarcinoma-derived cell line. Int J Cancer 1980, 25:19-32
29. Harlow E, Lane D: Antibodies: A Laboratory Manual. New York, Cold Spring Harbor Laboratory, 1988, pp 418
30. Duncan AR, Winter G: The binding site for C1q on IgG. Nature 1988, 332:738-740
31. Yamaguchi K, Sakiyama H, Matsumoto M, Moria H, Sakiyama S: Degradation of type I and II collagen by human C1s. FEBS Lett 1990, 268:206-208
32. Sakiyama H, Inaba N, Toyoguchi T, Okada Y, Matsumoto M, Moriya H, Ohtsu H: Immunolocalization of complement C1s and matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase) in the primary ossification center of human femur. Cell Tissue Res 1994, 227:239-245
33. Pemberton PA, Harnson RA, Lachrnann PJ, Carrell RW: The structural basis for neutrophil inactivation of C1 inhibitor. Biochem J 1989, 258:193-198
34. Knäuper V, Triebel S, Reinke H, Tschescke H: Inactivation of human plasma C1-inhibitor by human PMN leucocyte matrix metalloproteinases. FEBS Lett 1991, 290:99-102
35. 35: Hugli TE: Structure and functions oi anaphylotoxins. Springer Semin Immunopathol 1984, 7:193-219
36. Ross GD, Medof ME: Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985, 37:217-267
37. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT: C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350